Jefferies Group Research Analysts Lift Earnings Estimates for Johnson & Johnson (JNJ)

Johnson & Johnson (NYSE:JNJ) – Jefferies Group boosted their FY2018 earnings per share estimates for Johnson & Johnson in a report released on Tuesday. Jefferies Group analyst J. Holford now forecasts that the company will post earnings per share of $8.31 for the year, up from their previous estimate of $8.17. Jefferies Group has a “Buy” rating and a $160.00 price objective on the stock. Jefferies Group also issued estimates for Johnson & Johnson’s FY2022 earnings at $11.58 EPS.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, topping the Zacks’ consensus estimate of $1.80 by $0.10. The business had revenue of $19.65 billion for the quarter, compared to analyst estimates of $19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. Johnson & Johnson’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period last year, the company posted $1.68 earnings per share.

A number of other analysts have also commented on JNJ. Wells Fargo & Co reiterated an “outperform” rating and set a $160.00 price target (up from $155.00) on shares of Johnson & Johnson in a report on Friday, January 12th. Vetr lowered Johnson & Johnson from a “buy” rating to a “hold” rating and set a $147.40 price target on the stock. in a report on Monday, January 8th. Citigroup began coverage on Johnson & Johnson in a report on Monday, September 25th. They set a “neutral” rating and a $140.00 price target on the stock. BMO Capital Markets reiterated a “positive” rating and set a $152.00 price target (up from $145.00) on shares of Johnson & Johnson in a report on Wednesday, October 18th. Finally, Royal Bank of Canada lifted their price target on Johnson & Johnson from $144.00 to $147.00 and gave the stock an “outperform” rating in a report on Wednesday, October 18th. Four investment analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $145.94.

Shares of Johnson & Johnson (JNJ) traded down $0.06 during trading on Wednesday, reaching $146.92. The company had a trading volume of 5,550,000 shares, compared to its average volume of 6,050,000. The company has a market capitalization of $394,700.00, a price-to-earnings ratio of 25.51, a P/E/G ratio of 2.77 and a beta of 0.80. Johnson & Johnson has a 1-year low of $110.76 and a 1-year high of $148.32. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36.

Institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. grew its position in shares of Johnson & Johnson by 1.5% in the second quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock valued at $26,517,661,000 after purchasing an additional 3,023,110 shares in the last quarter. BlackRock Inc. grew its position in shares of Johnson & Johnson by 2.6% in the second quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock valued at $23,028,219,000 after purchasing an additional 4,332,612 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of Johnson & Johnson by 0.4% in the third quarter. Bank of New York Mellon Corp now owns 36,594,054 shares of the company’s stock valued at $4,757,593,000 after purchasing an additional 130,437 shares in the last quarter. FMR LLC grew its position in shares of Johnson & Johnson by 5.9% in the second quarter. FMR LLC now owns 27,237,648 shares of the company’s stock valued at $3,603,268,000 after purchasing an additional 1,509,745 shares in the last quarter. Finally, Capital World Investors grew its position in shares of Johnson & Johnson by 4.1% in the second quarter. Capital World Investors now owns 26,510,007 shares of the company’s stock valued at $3,507,009,000 after purchasing an additional 1,050,000 shares in the last quarter. Hedge funds and other institutional investors own 65.71% of the company’s stock.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Shareholders of record on Tuesday, February 27th will be paid a $0.84 dividend. The ex-dividend date is Monday, February 26th. This represents a $3.36 annualized dividend and a dividend yield of 2.29%. Johnson & Johnson’s payout ratio is presently 58.33%.

ILLEGAL ACTIVITY NOTICE: This story was originally published by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this story on another website, it was copied illegally and reposted in violation of United States & international trademark and copyright legislation. The original version of this story can be accessed at https://transcriptdaily.com/2018/01/18/jefferies-group-research-analysts-lift-earnings-estimates-for-johnson-johnson-jnj.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Earnings History and Estimates for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply